INTRODUCTION
============

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that regulates proliferation, differentiation, development, angiogenesis, wound healing and other functions in many cell types [@B044]. Regarding pathological disorders, such as cancer, TGF-β plays two conflicting roles of a tumor suppressor and a tumor promoter. TGF-β acts as a tumor suppressor in the early stage of cancer development, whereas in late stage it can take on role of tumor promoter, favoring of invasion and metastasis [@B051]; [@B057]. TGF-β is a one of members of a large superfamily of secreted proteins that include three TGF-β isoforms (TGF-β1, -β2 and -β3), activins, bone morphogenetic proteins (BMPs), inhibins, nodal, and others. Cancer cells, in general, secrete larger amounts of TGF-β than their normal counterparts [@B033]; [@B043]. TGF-β is secreted from the cell as an inactive latent homodimeric polypeptide bound to other extracellular proteins [@B064]; [@B054]. The mature, bioactive TGF-β is produced on proteolytic cleavage of the latent complex. TGF-β interacts with its four receptor subunits that interact not only with TGF-β, but also with each other. Understanding the detailed mechanism of the interactions between TGF-β and its receptors presents potential opportunities to find new drugs. Such drugs or blockades could be designed to inhibit the assembly of the TGF-β signaling complex and in turn eliminate its tumor-promoting activities.

THE MECHANISM OF TGF-β SIGNALING
================================

TGF-β1 binds with high affinity and selectivity to the transmembrane TGF-β type II receptor (TβRII), and this recruits the TGF-β type I receptor (TβRI or ALK5) and activates TβR1 kinase ([Fig. 1](#F001){ref-type="fig"}). Activated TβR1 then initiates canonical Smad signaling by phosphorylation of receptor-associated Smads (R-Smads), Smad2, and Smad3. The phosphorylated Smad2/3 forms a complex with Smad4, the common mediator Smad, and translocate into the nucleus. In the nucleus, Smad complexes accomplish high affinity binding to Smad-binding elements within the promoter region of TGF-β target genes, showing TGF-β dependent transcription [@B070]. TβRI and TβRII are transmembrane serine/threonine kinases, and there are seven TβRIs and five TβRIIs are identified in humans [@B057]. TβRI and TβRII are paired in different combinations for different ligands, for example, TGF-β1 signaling needs ALK5/ TβRII combination in most cells. Smads are intracellular proteins characterized by Mad homologous domain at N-terminus (MH-1) and at C-terminus (MH-2), and linker connecting between these two MH-1 and MH-2 domains. The linker recruits ubiquitin ligases (E3 ligase, and smurfs) and is phosphorylated by other kinases such as MAPK and cyclin dependent kinases [@B044]. TGF-β can also signal through Smad-independent signaling, including the PI3 kinase, MAPK, TRAF6-TAK1 and RhoA-Rock pathways [@B015] ([Fig. 1](#F001){ref-type="fig"}). The antagonistic Smads, Smad-6 and Smad-7, are thought to function by blocking ligand-dependent signaling [@B028]; [@B092]. The canonical TGF-β/Smad signaling pathway is essential to the growth inhibitory action of TGF-β, however, the relative contribution of canonical and non-canonical pathways to other TGF-β regulated biological processes, such as EMT and apoptosis, is still under investigation.

TGF-β AS A TUMOR SUPPRESSOR
===========================

Mutations in genes of the components of TGF-β signaling have been identified and mutations in TβRII, TβRI, Smad-2 and Smad-4 are most common. These mutations are observed in GI tract cancers such as colorectal cancer (CRC), in gastric, pancreatic, biliary tract, lung and brain (glioma) tumors [@B025]; [@B038]. The TβRII gene mutations are abundant, because TβRII is a mutational hotspot due to its 10 base poly-A repeat within its coding sequence [@B042]; [@B061]; [@B001]; [@B074]; [@B024]; [@B009]. Mutations in TβRI are not as frequent as Tβ RII, although they have been described in pancreatic, colorectal, ovarian and head and neck cancers [@B022]; [@B085]; [@B008]. Mutations of TβRII and TβRI are relatively rare in breast, skin and hematological cancers [@B016]; [@B038]; [@B009]. A number of mutations in Smad-2 and Smad-4 have been identified in pancreas, ovarian, cervical, liver, CRC, lung, and other cancers [@B018]; [@B088]; [@B085]; [@B040]. The genetic studies from human tumors argue that the Smad-dependent TGF-β pathway acts as a tumor suppressor in many types of human cancers, particularly those of the GI tract. The action of TGF-β as a tumor suppressor is shown by functional inactivation of receptors and Smads, and elevated expression of TGF-β signaling in human carcinoma and in mouse tumor models [@B012]. TGF-β controls cell proliferation mainly by inhibiting cell cycle progression through G1-arrest ([Fig. 2](#F002){ref-type="fig"}). In most epithelial, endothelial and hematopoietic cells, TGF-β arrest cell cycle at G1 by inducing or activating cdk inhibitors such as, p16INK4A, p15INK4B, p21CIP1 and/or p27Kip1 [@B045]. TGF-β inhibited transcription factors, such as Myc, Id1 and Id2, involved in proliferation and differentiation. In most tumor cells where TGF-β signaling is disrupted by somatic mutation, TGF-β is incapable of inducing p15Ink4b andp21Cip1 and inhibiting Myc and Id proteins. This tumor-suppressive function of TGF-β has raised concerns about the use of TGF-β antagonists to treat cancer, despite the increasingly strong evidence that TGF-β1 can promote tumor metastasis.

![TGF-β signaling through Smad-dependent and Smad-independent pathways. (A) Canonical pathway. TGF-β ligands activated TGF- βRI and TGF-βRII receptor complex recruits and phosphorylates the receptor specific Smad2/3. Hetero-oligomeric complex of Smad2/3- Smad4 translocates to the nucleus and binds to specific DNA sequence and interacts with transcription factors and cofactors to regulate transcription. The pathway is negatively regulated by the Smad6/7, which bind activated TGF-βRI, thereby preventing phosphorylation of Smad2/3, or recruit the E3 ubiquitine ligases to induce proteasomal degradation of the Smad2/3 (B) Noncanonical pathway. Smad-independent signaling. TGF-β can promote the activity of several signaling pathways other than Smad, including MAPKs, PI3K kinases, TRAF6- TAK1-p38/JNK, Rho-Rock, among others.](ooomb4-21-323-g001){#F001}

TGF-β AS A TUMOR PROMOTER
=========================

It is widely accepted that during the late stage of tumor progress, inhibitory effects of TGF-β on cell proliferation are lost [@B063]; [@B080]; [@B067] ([Fig. 3](#F003){ref-type="fig"}). The prominent mechanisms of TGF-β on tumor progression are epithelial-to-mesenchymal transition (EMT), tumor stroma interaction and microenvironment, and circumvention of the immune system [@B084]; [@B013]. During EMT, the cells lose their polarity and cell-cell contact by decreasing the expression of E-cadherin and other components of the cell junction and increasing the expression of N-cadherin and other components of extracellular matrix [@B077]. EMT is a highly coordinated process in response to stress, such as inflammation or wounding during embryonic development, neoplasia and fibrosis [@B008]. TGF-β induces EMT by Smad-dependent transcriptional events and enhanced by Smad-independent Ras signaling late stages of tumorigenesis [@B051]. Smads act as transcriptional regulatory factors of EMT regulators such as Snail/Slug/Twist, Cripto-1 and Six1 [@B079]; [@B049]; [@B083]; [@B039]; [@B050]; [@B086]; [@B072]. Recent study suggests that EMT-inducing factors such as Twist, Snail and TGF-β may induce the expression of cell surface markers associated with cancer stem cells and these cells share high homology to bone marrow-derived mesenchymal stem cells [@B041]. When the immunosuppressive effects of TGF-β become dominant, the net effect favors tumor progression, even though TGF-β has anti-inflammatory effects which result in tumor suppression [@B044]. In CTLs, TGF-β suppresses transcription of factors, such as granzyme, perforin, interferon-g and FAS ligand [@B078]; [@B048]. TGF-β can inhibit both CD4^+^ and CD8^+^ T cells as well as on natural killer (NK) cells by inhibiting the function of antigen presenting cells [@B002]. TGF-β shifts the immune response from differentiated anti-tumor cells into the immature cells that can release TGF-β and IL-11 into the tumor environment [@B020]; [@B009].TGF-β increases angiogenesis, activities of metalloproteases MMP-2 and MMP- 9, and inhibits protease inhibitor TIMP [@B014]; [@B026]; [@B066]; [@B031]; [@B057]. Role of TGF-β in tumor metastasis was observed in numerous models of cancer, such as the collagen-embedded spheroid system [@B087] and other three-dimensional co-culture assays [@B037]. TGF-β is a major contributor to the bone metastases, and TGF-β is released from bone matrix by the activated osteoclasts that degrade the bone matrix. Secreted TGF-β stimulates releasing of other osteolytic cytokines, such as parathyroid hormone related protein (PTH-rP), IL-11 and CTGF from the metastatic cells to maintain the metastatic process [@B034]. Smad-3 and -4 for bone, and Smad-2 for lung, liver and brain are necessary for the metastatic expansion, respectively [@B030]; [@B044]; [@B048]. The induction of the angiopoietin-like 4 (ANGPTL4) gene by TGF-β in the primary tumor is the key for cancer cells to leave the breast in order to disrupt the lung capillary walls, results in the TGF-βinduced lung metastasis [@B058]. Because ANGPTL4 do not work on the fenestrated capillaries of the bone marrow TGF-β can direct breast cancer cell to lung and not to bone metastasis [@B044].

![TGF-β signaling in tumor suppression. TGF-β inhibits cell proliferation by increases in expression of cyclin-dependent kinase (CDK) inhibitors p21 and p15 and decrease in expression of proliferative drivers such as c-Myc and ID. TGF-β also effects on apoptosis and cell differentiation, genomic stability, tumor stroma, and inflammation.](ooomb4-21-323-g002){#F002}

![TGF-β signaling in tumor promotion. TGF-β promotes tumor progression by mechanisms, such as EMT, metastasis, angiogenesis, immune modulation, and tumor microenvironment. APC: antigen presenting cells; EMT: epithelial-to-mesenchymal transition; NK: natural killer.](ooomb4-21-323-g003){#F003}

THERAPEUTIC INHIBITORS OF TGF-β SIGNALING
=========================================

Studies support targeting TGF-β signaling as an anti-cancer therapeutic strategy ([Fig. 4](#F004){ref-type="fig"}). Currently, therapeutic strategies against TGF-β can be divided into three approaches: i) prevention of TGF-β synthesis by using antisense molecules; ii) inhibition of the ligand-receptor interaction by ligand traps (monoclonal antibodies and soluble receptors) and anti-receptor monoclonal antibodies; and iii) inhibition of the receptormediated signaling cascade, using TGF-β receptor kinases inhibitors and aptamers [@B057]. For each of these approaches, several drugs have been developed and are either in non-clinical or in early stages of clinical investigation.

Since TGF-β level is often elevated during tumor progression, inhibiting its synthesis has the potential to decrease TGF-β levels within the tumor microenvironment. AP12009 (Trabedersen, Antisense, Pharma) is an antisense molecule against TGF-β 2, whose expression is associated with poor prognosis in glioblastoma and pancreatic cancer. Trabedersen (AP12009) showed the efficacy in a mouse model of pancreatic cancer and was successfully tested in Phase I/II study in patients with refractory high grade glioma [@B027]; [@B069]. AP11014 and AP15012 are other two antisense molecules in pre-clinical trials for treatment of non-small cell lung cancer, prostate carcinoma and CRC, and malignant melanoma (MM), respectively [@B036].

A monoclonal antibody (mAB), 1D11 (Genzyme Corp., Sanofi), that binds TGF-β 1, 2 and 3, resulted in suppression of lung metastasis in metastatic breast cancer mouse model, by increase in the antitumor response of CD8^+^ T-cells [@B056]. It also decreased bone loss by reduced expression of PTHrP and its regulatorGli2 [@B009]. 2G7, another mAB in pre-clinical trials, showed efficacy in inhibiting breast cancer metastasis by increasing NK cells activity [@B002]; [@B004]; [@B021]. Three humanized mABs, GC-1008 (Fresolimumab), CAT-152 (Lerdelimimab) and CAT-192 (Metelimumab) were developed by Genzyme and tried in clinical trial. GC-1008 was tested in Phase I/II clinical trial and two trials of GC-1008 are in recruitment phase: Fresolimumab and radiotherapy in metastatic breast cancer (NCT01401062) and safety and imaging study of GC1008 in glioma (NCT01472731). Soluble TβRII and TβRIII (betaglycan) have been tested in pre-clinical studies in breast and pancreatic cancer metastasis [@B055]; [@B065]; [@B089]; [@B048], but no clinical trials have been undertaken with these soluble receptors. PF-03446962 is an anti-TβRI mAB which inhibits binding to ligands BMP9 and TGF-β to TβRI and can serve as an anti-angiogenesis agent by inhibiting endothelial cell sprouting [@B082]. PF-03446962 is in recruitment phase: malignant pleural mesothelioma (NCT01486368).

![TGF-β signaling pathway inhibitors under development for potential cancer therapy. (blue line box) Antisense molecules inhibit TGF-β synthesis; (black line box) monoclonal antibodies, soluble receptors and anti-receptor monoclonal antibodies inhibit ligand-receptor interaction; (red line box) receptor kinase inhibitors and peptide aptamers (purple line box) inhibit signal transduction.](ooomb4-21-323-g004){#F004}

Small molecules targeting receptor kinases have been extensively investigated and these are more efficient TGF-β signaling blockers than mAB and antisense molecules [@B009]. SB-431542 and SB-505124 (GlaxoSmithKline), small molecule inhibitors of TβRI, inhibit phosphorylation of Smad-2/3, TGF-β -induced proliferation, motility and angiogenesis of glioma cells, and transcription of collagen and fibronectin in renal carcinoma cells [@B046]; [@B011]; [@B029]; [@B006]. SB-431542 also increases dendritic cells maturation, CD8^+^ T cell activity [@B075]; [@B076]; [@B009]. However, these two inhibitors are not stable and specific so that they can draw to unpredictable outcomes and side effects.Ki26894 and LY364937 (Eli-Lilly & Co) are other TβRI inhibitors which appeared to be promising in terms of inhibiting metastasis to bone and experiments using breast and gastric cell line in in vitro [@B017]; [@B071] and xenografts mouse model *in vivo* [@B003]; [@B017]. LY2109761 (Eli-Lilly & Co) is a small molecule which is TβRI-specific (Ki= 38 nM for TβRI kinase vs IC50 of 300 nM for TβRII) inhibitor, and is relatively metabolically stable and suitable for *in vivo* studies. *In vivo* mouse pancreas and colon metastasis model, LY-2109761 decreased liver metastases and prolonged survival [@B007]; [@B019]; [@B047]; [@B035]; [@B091]. However, long-term use of this drug in a skin cancer mouse model resulted in resistance and cancer progression [@B010], suggesting that more than one drug may be needed for long-term inhibition of one signaling pathway [@B009]. SD-093 and SD-208, LY- 580276 [@B068], which act as competitive inhibitors for the ATP-binding site of TβRI kinase showed anti-metastasis effect in glioma [@B081] and metastatic mouse models [@B073]; [@B081]; [@B090]; [@B052]. SD-093 and LY-580276 have been shown to block EMT and tumor cell migration in pancreatic cancer and mouse mammary epithelial cells, respectively [@B073]; [@B062]. TGF-β/ALK5 kinase inhibitor, LY-573636, is tested in patients with malignant melanoma, soft-tissue sarcoma, NSCLC, and ovarian cancer [@B023]. IN-1130, a TβRI kinase inhibitor suppresses renal fibrosis in obstructive nephropathy and metastasis from breast to lung [@B053]. Recently, potent and highly specific TGF-β/ALK5 inhibitors, EW-7203 [@B060], EW-7195 [@B059], and EW-7197 [@B032] were developed as orally available drugs. EW- 7203, EW-7195, and EW-7197 inhibited Smad/TGF-β signaling, cell migration, invasion, and lung metastasis of breast cancer cells in 4T1 and MDA-MB-231 orthotropic xenograft mice and MMTV/cNeu transgenic mice. They inhibited epithelial to mesenchymal transition (EMT) in both TGF-β treated breast cancer cells and 4T1 orthotropic xenograft mice. 1.25 mg/ Kg EW-7197 increased the survival time of 4T1-Luc and 4T1 breast tumor bearing mice [@B032]. Pre-clinical study with EW-7197 was completed and ready for the clinical trial. LY2157299 (Eli-Lilly & Co) is the only TGF-β receptor kinase inhibitor currently in clinical trial and a TβRI kinase inhibitor that reduces growth of lung and breast cell lines [@B005]. LY2157299 was well tolerated at all doses from patient with Grade IV glioma. A pulmonary embolism and thrombocytopenia were two drug-related dose limiting toxicities and currently, LY2157299 is tested in four clinical trials, all of them are still recruiting patients: Phase Ib/II in stage II-IV pancreatic cancer of LY2157299 combined with gemcitabine versus gemcitabine plus placebo (NCT01373164); Phase II in HCC patients who have had disease progression on Sorafenib or are not eligible to receive sorafenib (NCT01246986); Phase Ib/IIa study combining LY2157299 with standard Temozolomide based radiochemotherapy in patients with newly diagnosed malignant glioma (NCT01220271); and Phase II Study ofLY2157299 mono therapy or LY2157299 plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent glioblastoma (NCT01582269).

CONCLUSIONS
===========

TGF-β pathway is being extensively evaluated as a potential therapeutic target [@B090]. Because of the dual role of TGF-β in tumorigenesis, a comprehensive understanding of TGF-β biology is required for the design successful therapeutics. It is important to discover new drugs that mimic the interactions between TGF-β and its receptors and mechanistically inhibit transduction of the TGF-β signaling and in turn eliminate the tumor-promoting activities of TGF-βs. The TGF-β inhibitors are in pre-clinical studies, and Phase I and II clinical trials. Preclinical studies have provided convincing evidence that targeting the TGF-β pathway is able to inhibit tumor growth and metastasis *in vivo*. And the results from clinical trial are encouraging for further new drug development.
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